Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 8/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 2/20 | 0.36 |
| ▸ | IDH2 | P48735 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618367 | 1.00 | FAAH (0.41) | FAAHKDRMAPK14TNNI3KCSNK1D | |
| SCHEMBL19365762 | 0.96 | FAAH (0.40) | FAAHKDRMAPK14TNNI3KCSNK1D | |
| SCHEMBL17618373 | 0.96 | FAAH (0.40) | FAAHKDRMAPK14TNNI3KCSNK1D | |
| SCHEMBL16775963 | 0.95 | FAAH (0.42) | FAAHKDRMAPK14TNNI3KCSNK1D | |
| SCHEMBL17618572 | 0.90 | ABL1 (0.37) | FAAHKDRFGFR4BRAFABL1 | |
| SCHEMBL19699059 | 0.90 | FAAH (0.43) | FAAHCSNK1DCSNK1EFGFR4 | |
| SCHEMBL17618447 | 0.90 | KIT (0.41) | FAAHKDRMAPK14CSNK1DCSNK1E | |
| SCHEMBL17618356 | 0.90 | NPC1 (0.38) | PHGDHIDH2KDM1AMAOAMAOB | |
| SCHEMBL17618425 | 0.89 | FAAH (0.42) | FAAHCSNK1DCSNK1EFGFR4 | |
| SCHEMBL17618449 | 0.88 | HPGDS (0.38) | FAAHFGFR4RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FAAH 977/4885KDR 1697/4885MAPK14 2116/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | FAAH 977/4885KDR 1697/4885MAPK14 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.